Thrombosis prevention in heparin-induced thrombocytopenia

Thrombosis prevention in heparin-induced thrombocytopenia refers to the prophylactic management of patients diagnosed with or suspected of having heparin-induced thrombocytopenia (HIT) who have not yet manifested overt thromboembolic events Consequently, affected individuals remain at an exceptionally high risk for developing life- or limb-threatening venous and arterial thromboembolisms, necessitating immediate alternative systemic anticoagulation to avert new clot formation

Thrombosis prevention in heparin-induced thrombocytopenia refers to the prophylactic management of patients diagnosed with or suspected of having heparin-induced thrombocytopenia (HIT) who have not yet manifested overt thromboembolic events

This clinical state affects the vascular and hematologic systems following exposure to unfractionated or low-molecular-weight heparin, wherein IgG autoantibodies target platelet factor 4 (PF4)–heparin complexes Although characterized by a precipitous drop in circulating platelet counts, these immune complexes paradoxically trigger widespread platelet activation, thrombin generation, and endothelial injury Consequently, affected individuals remain at an exceptionally high risk for developing life...

This clinical state affects the vascular and hematologic systems following exposure to unfractionated or low-molecular-weight heparin, wherein IgG autoantibodies target platelet factor 4 (PF4)–heparin complexes Although characterized by a precipitous drop in circulating platelet counts, these immune complexes paradoxically trigger widespread platelet activation, thrombin generation, and endothelial injury Consequently, affected individuals remain at an exceptionally high risk for developing life...

Although characterized by a precipitous drop in circulating platelet counts, these immune complexes paradoxically trigger widespread platelet activation, thrombin generation, and endothelial injury